研究表明,尽管一线化疗联合抗血管生成治疗在KRASm NSCLC患者中的疗效仍低于KRASwt患者,但确实改善了KRAS突变患者的生存期。Ghimessy等的研究发现,接受化疗联合贝伐珠单抗治疗的KRASm晚期肺腺癌患者,其OS和PFS均显著低于KRASwt患者(OS:14.23个月 vs. 21.57个...
Results: Relative to KRASmut/STK11wttumors, KRASmut/STK11mut exhibited significantly higher recurrence risk. Single-cell transcriptomics showed enhanced oxidative phosphorylation with evidence of decreased PGE-2 signaling and increased IL-2 signaling in CD...
e, Live cell target engagement is observed at WT KRAS with BI-2852, but not with AMG510 (1). BRET is normalized relative to a saturating (20 µM) dose of BI-2852, as marked. RLU stands for relative luminescence units. Source data Full size image To determine whether the RAS BRET...
specificity of the GpRs and exclude “off-targets” effects, we deleted the region inKIMAT1necessary for the GpRs binding (Supplementary Fig.5d). While, cells transfected with a plasmid harboringKIMAT1WT showed reduced 3D cell invasion and colony formation upon GpRs transfection, cells overexpressin...
I-138 诱导 MDA-MB-436 细胞中 FANCD2 和 PCNA 的单泛素化,增加 HAP-1 USP1 WT 细胞中的 PCNA 和 FANCD2 单泛素化。 MC-GGFG-AM-(10Me-11F-Camptothecin) ZW251 的 Linker-Payload,ZW251 是一种靶向人 GPC3 的抗体-药物偶联物 (ADC)。
(Wt)cell-lines Caco2 and Colo-320.DLD-1(KRAS),HT-29(BRAF)and Caco2(Wt)cell lines were treated with cytokines(TNF伪50 ng,IL-1尾1 ng and IFN纬50ng)and harvested at different time points(1-24 h).KRAS inhibition was performed by the siRNA-approach.Two colorectal cancer cells DLD-1 ...
此次批准,基于III期IMpower110研究的结果,试验显示,在PD-L1高表达(TC3/IC3-WT)患者中,与化疗相比,Tecentriq单药一线治疗将总生存期(OS)显著提高了7.1个月(中位OS:20.2个月 vs 13.1个月),且不良反应安全可控。 ⑨奥希替尼获批术后辅助治疗 12月21日,奥希替尼被美国FDA获批,作为一种辅助(术后)疗法,用于治疗...
NDA申请是基于一项多中心、随机、开放标签的II期RAMP 201临床试验的结果,截至2024年6月30日,经BICR确认,随访约12个月,在 KRAS 突变 (mt) LGSOC 患者中,ORR 为 44% ,DOR 为 31.1 个月,PFS 为 22 个月,DCR 为 70%;在 KRAS 野生型 (wt) LGSOC 患者中,ORR 为 17%,DOR 为 9.2 个月,PFS 为 12.8...
TargetCell LineKRAS Mutation Status MEK1/2 PANC-1 G12D ASPC-1 G12D Mia-Pa-Ca-2 G12C NCI-H358 G12C SW-620 G12V BxPC-3 WT HT-29 WT All of these cell lines are also established in the 3D spheroid assay. To enquire about additional cell lines or request more information: Contact...
Furthermore, the combination of KRAS (G12C) inhibitor and WT RAS upstream activators, such as SHP2, is synergistic [105, 106]. SHP2 inhibitors can restore the sensitivity of KRAS-mutant NSCLC to MEK inhibition and increase inactive GDP-bound KRAS. A triplet combination of KRAS (G12C), ...